Published in Nat Rev Cardiol on April 21, 2016
Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med (2011) 0.99
Coronary artery disease: Predicting the progression of coronary artery calcification. Nat Rev Cardiol (2014) 0.78
Imaging. Effect of CT coronary angiography on the diagnosis and outcomes of patients with CAD. Nat Rev Cardiol (2015) 0.77
Hypertension: PATHWAY to improving the treatment of drug-resistant hypertension. Nat Rev Nephrol (2015) 0.76
Risk factors. Reducing alcohol intake improves heart health. Nat Rev Cardiol (2014) 0.76
Coronary disease: Sex differences in CAD diagnosis. Nat Rev Cardiol (2016) 0.75
Anticoagulation therapy: Benefits of extended oral anticoagulation after first episode of pulmonary embolism. Nat Rev Cardiol (2015) 0.75
Basic research: Kidneys and cardiac stress. Nat Rev Cardiol (2017) 0.75
Valvular disease: Transcatheter repair of severe tricuspid regurgitation. Nat Rev Cardiol (2017) 0.75
Vascular disease: Cell therapy lowers PAD amputation risk. Nat Rev Cardiol (2017) 0.75
Diabetes: Lixisenatide does not increase rates of CVD events. Nat Rev Cardiol (2015) 0.75
Stem cells: Allogenic mesenchymal stem cells for dilated cardiomyopathy. Nat Rev Cardiol (2017) 0.75
Antiplatelet therapy: risks and benefits of extended DAPT after stenting. Nat Rev Cardiol (2014) 0.75
Hypertension: PATHWAY to improving the treatment of drug-resistant hypertension. Nat Rev Cardiol (2015) 0.75
Genetics: Non-HDL cholesterol confers increased risk of CAD. Nat Rev Cardiol (2016) 0.75
Dyslipidaemia: Evolocumab lowers LDL cholesterol. Nat Rev Cardiol (2014) 0.75
Cardiomyopathies: Clinical features of patients with Takotsubo syndrome. Nat Rev Cardiol (2015) 0.75
Cardiac resuscitation: Optimal duration of prehospital resuscitation after OHCA. Nat Rev Cardiol (2016) 0.75
Dyslipidaemia: Niacin-laropiprant fails to reduce the risk of vascular events. Nat Rev Cardiol (2014) 0.75
Heart failure: Lung-impedance-guided therapy for chronic heart failure. Nat Rev Cardiol (2016) 0.75
Pharmacotherapy. Benefit of testosterone replacement therapy on CVD and mortality. Nat Rev Cardiol (2015) 0.75
Arrhythmias: Arrhythmia risk stratification using virtual heart models. Nat Rev Cardiol (2016) 0.75
Atherosclerosis: low-dose aspirin failed to improve cardiovascular outcomes. Nat Rev Cardiol (2014) 0.75
Risk factors: Negative risk markers for CVD. Nat Rev Cardiol (2016) 0.75
Venous thromboembolism: Risk of recurrence lower with rivaroxaban than aspirin. Nat Rev Cardiol (2017) 0.75
Venous thromboembolism: 5-year follow-up data from CaVenT. Nat Rev Cardiol (2016) 0.75
Hypertension: Initial combination therapy improves PAH. Nat Rev Cardiol (2015) 0.75
Heart failure: Improvement of LVEF in patients with HF is linked to better prognosis. Nat Rev Cardiol (2016) 0.75
Atherosclerosis: Regression of coronary atherosclerosis with statin therapy. Nat Rev Cardiol (2014) 0.75
Heart failure: Interarterial shunt device for HFpEF. Nat Rev Cardiol (2016) 0.75
Hypertension: SPRINTing towards a new target for blood-pressure control. Nat Rev Cardiol (2015) 0.75
Heart failure: HF-induced diaphragmatic atrophy and weakness. Nat Rev Cardiol (2017) 0.75
Heart failure: CA125-guided therapy reduces AHF rehospitalizations. Nat Rev Cardiol (2016) 0.75
Atherosclerosis: Carotid artery stenting versus endarterectomy--no difference in long-term outcomes. Nat Rev Cardiol (2014) 0.75
Acute coronary syndromes: Bivalirudin versus heparin for ACS. Nat Rev Cardiol (2015) 0.75
Coronary artery disease: Ceramides predict CV death in stable CAD and ACS. Nat Rev Cardiol (2016) 0.75
Hypertension: Very low achieved SBP increases risk of cardiovascular death. Nat Rev Cardiol (2017) 0.75
Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab. Nat Rev Cardiol (2015) 0.75
Vascular disease: Vorapaxar for the treatment of PAD. Nat Rev Cardiol (2016) 0.75
Diabetes: Diabetes-induced microvascular destabilization. Nat Rev Cardiol (2017) 0.75
Antiplatelet therapy: Clopidogrel plus aspirin reduces migrane attacks after ASD closure. Nat Rev Cardiol (2015) 0.75
Gene therapy. Inhibiting apoC-III synthesis in patients with hypertriglyceridaemia. Nat Rev Cardiol (2015) 0.75
Basic research: Cardioprotective benefits of dietary spermidine. Nat Rev Cardiol (2017) 0.75
Gene therapy: Targeting apoc-III to lower triglycerides. Nat Rev Cardiol (2014) 0.75
Antiplatelet therapy: Ticagrelor reduces cardiac events in patients with PAD or diabetes. Nat Rev Cardiol (2016) 0.75
Heart failure: Thoracic spinal cord stimulation for the treatment of HF. Nat Rev Cardiol (2015) 0.75
Vascular diseases: Shear-thinning biomaterial for endovascular embolization. Nat Rev Cardiol (2016) 0.75
Interventional cardiology: 6-year follow-up of TAVI patients. Nat Rev Cardiol (2015) 0.75
Risk factors: Sodium intake and health outcomes. Nat Rev Cardiol (2014) 0.75
Heart failure: Neprilysin inhibition attenuates risk of hyperkalaemia in HFrEF. Nat Rev Cardiol (2016) 0.75
Coronary artery disease: Gastroprotection in patients with CAD requiring DAPT. Nat Rev Cardiol (2016) 0.75
Arrhythmias: Amiodarone fails to lower AF recurrence in AMIO-CAT trial. Nat Rev Cardiol (2014) 0.75
Interventional cardiology: Preventing heart failure after STEMI with a cardiac matrix. Nat Rev Cardiol (2016) 0.75
Imaging: Combining IVUS and NIRS improves accuracy of fibroatheroma detection. Nat Rev Cardiol (2015) 0.75
Biomarkers: High-sensitivity troponin assays for the diagnosis of AMI-sex-specific differences? Nat Rev Cardiol (2015) 0.75
Acute coronary syndromes: Utility of measuring fractional flow reserve by CT angiography in patients with suspected CAD. Nat Rev Cardiol (2015) 0.75
Valvular disease: vWF testing for paravalvular regurgitation during TAVI. Nat Rev Cardiol (2016) 0.75
Imaging: OCT-guided PCI improves procedural strategy. Nat Rev Cardiol (2016) 0.75
Atherosclerosis: TREM1 in atherosclerosis development. Nat Rev Cardiol (2017) 0.75
Heart failure: Ketone bodies as fuel in heart failure. Nat Rev Cardiol (2016) 0.75
Heart failure: Finerenone vs eplerenone for patients with HFrEF. Nat Rev Cardiol (2016) 0.75
Interventional cardiology: TAVR improves survival in inoperable patients with severe aortic stenosis. Nat Rev Cardiol (2015) 0.75
Thrombosis: Leaflet motion after TAVI or SAVR. Nat Rev Cardiol (2015) 0.75
Atrial fibrillation. Adenosine testing during catheter ablation of AF reduces recurrent atrial tachyarrhythmia. Nat Rev Cardiol (2015) 0.75
Anticoagulation therapy. Optimal dosages and genotypes for edoxaban therapy. Nat Rev Cardiol (2015) 0.75
Cardioprotection: Therapeutic hypothermia in STEMI. Nat Rev Cardiol (2016) 0.75
Genetics: Postmortem genetic testing uncovers causes of SCD in young individuals. Nat Rev Cardiol (2016) 0.75
Acute coronary syndromes: Similar bleeding risks with low-dose rivaroxaban versus aspirin. Nat Rev Cardiol (2017) 0.75
Atherosclerosis: PCSK9 inhibition reduces cardiovascular events in high-risk patients. Nat Rev Cardiol (2017) 0.75
Prevention: No cardiovascular benefit with CPAP use in patients with OSA. Nat Rev Cardiol (2016) 0.75
Arrhythmias: Results from the WEARIT-II registry. Nat Rev Cardiol (2015) 0.75
Hypertension: Tight control of hypertension is safe in pregnant women. Nat Rev Cardiol (2015) 0.75
Device therapy: Newly designed leadless pacemaker. Nat Rev Cardiol (2015) 0.75
Device therapy: Optimization of CRT with novel contractility sensor. Nat Rev Cardiol (2017) 0.75
Atrial fibrillation. Weight loss reduces AF burden. Nat Rev Cardiol (2015) 0.75
Device therapy: High-zone programming of ICDs reduces inappropriate shocks. Nat Rev Cardiol (2015) 0.75
Hypertension: New study REVEALs no survival benefit of warfarin for IPAH. Nat Rev Cardiol (2015) 0.75
Anticoagulation therapy: Reversal of factor Xa activity. Nat Rev Cardiol (2016) 0.75
Peripheral artery disease: Drug-coated balloon superior to standard balloon angioplasty. Nat Rev Cardiol (2017) 0.75
Surgery: Survival benefit of CABG surgery for ischaemic cardiomyopathy. Nat Rev Cardiol (2016) 0.75
Basic research: New cardiomyocyte formation in adult mouse hearts. Nat Rev Cardiol (2017) 0.75
Newly designed leadless pacemaker. Nat Rev Cardiol (2016) 0.75
Risk factors: Low educational attainment linked to high CVD risk. Nat Rev Cardiol (2017) 0.75
Heart failure: Gut-derived metabolite is a predictor in acute HF. Nat Rev Cardiol (2016) 0.75
Developmental biology: Formation of hybrid myocardial zone. Nat Rev Cardiol (2017) 0.75
Coronary artery disease: Coronary artery calcium testing. Nat Rev Cardiol (2017) 0.75
Cerebrovascular disease: Pioglitazone reduces risk of stroke or MI. Nat Rev Cardiol (2016) 0.75
Anticoagulation therapy: Oral anticoagulants reduce dementia risk in patients with AF. Nat Rev Cardiol (2017) 0.75
Diabetes: Lower risk of cardiovascular death with canagliflozin. Nat Rev Cardiol (2017) 0.75
Surgery: Single vs bilateral artery grafts. Nat Rev Cardiol (2016) 0.75
Basic research: Minimally invasive delivery of engineered cardiac patches for heart repair. Nat Rev Cardiol (2017) 0.75
Dyslipidaemia: Monoclonal antibody targeting lipoprotein-bound human apoC-III. Nat Rev Cardiol (2017) 0.75
Lipids: Very low achieved LDL-cholesterol levels improve cardiovascular outcomes. Nat Rev Cardiol (2017) 0.75
Valvular disease: Bivalirudin versus heparin for the treatment of cerebral embolization post-TAVR. Nat Rev Cardiol (2016) 0.75
Inflammation: Targeting inflammatory pathways to treat atherosclerosis and cancer. Nat Rev Cardiol (2017) 0.75
Biomarkers: Lymphocyte GRK2 levels predict HF prognosis. Nat Rev Cardiol (2016) 0.75
Pharmacotherapy: Aspirin discontinuation increases risk of cardiovascular events. Nat Rev Cardiol (2017) 0.75
Basic research: Inhibition of Hippo pathway signalling reverses systolic heart failure. Nat Rev Cardiol (2017) 0.75
Atherosclerosis: Somatic mutations in haematopoietic cells contribute to atherosclerosis. Nat Rev Cardiol (2017) 0.75
Valvular disease: Cadherin 11 in calcific aortic valve disease. Nat Rev Cardiol (2017) 0.75